For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
State Directed Payments redistribute money across states and supercharged growth
Differences in states’ use of SDPs cause an interstate redistribution of taxes as well. Because states are setting different levels of SDPs, spending varies…
Blog
How State Directed Payments turned Medicaid into an interstate transfer scheme
Medicaid’s financing rules have long allowed states to expand spending while shifting much of the cost to federal taxpayers. One of the most important…
Blog
Medicaid financing gimmickry – before and after the One Big Beautiful Bill
Medicaid was created in 1965 as a joint federal-state health insurance program for low-income individuals which targeted families with dependent children, the elderly, and…
Search Posts
Op-Eds
The Quotable Fred
Full Booklet Available in PDF Format Executive Summary A compendium of quotes from the writings and speeches of CEI president and…
Citation
Trouble Standards
Op-Eds
Auto Fuel Economy Standards: Good For The Environment? Or A Cause Of Highway Deaths?
Full Policy Brief Available in PDF Format Executive Summary The Corporate Average Fuel Economy Program was part of legislation…
Op-Eds
Deadly Overcaution: FDA’s Drug Approval Process
Full article available in PDF When the federal Food and Drug Administration announces its approval of an important new drug, the…
Op-Eds
The Liberating Benefits Of Automobility
Full Article Available in PDF Format American’s love affair with the automobile has become…
Op-Eds
Biotechnology Flirts with the Regulators
Biotechnology, like other unfamiliar high tech industries, offers great hopes but arouses even greater fears. Politicians, the record proves, are far more likely to respond to…